Vertex Pharmaceuticals (VRTX) Expected to Announce Earnings on Monday

Key Points

• Vertex Pharmaceuticals is set to release its Q2 2025 earnings on August 4th, with analysts expecting earnings of $4.24 per share and revenue of $2.90 billion.
• In its previous quarter, Vertex reported an EPS of $4.06, which missed analysts' expectations, and had a revenue increase of only 2.6% year-over-year.
• The stock currently holds a consensus rating of "Moderate Buy" with an average price target of $512.30 from various analysts.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 4th. Analysts expect Vertex Pharmaceuticals to post earnings of $4.24 per share and revenue of $2.90 billion for the quarter. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the prior year, the business posted $4.76 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 2.6% compared to the same quarter last year. On average, analysts expect Vertex Pharmaceuticals to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:VRTX traded down $8.18 during midday trading on Thursday, hitting $460.99. The stock had a trading volume of 671,317 shares, compared to its average volume of 1,512,473. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The business's 50-day simple moving average is $454.64 and its 200-day simple moving average is $465.82. The company has a market cap of $118.38 billion, a P/E ratio of -117.67 and a beta of 0.41.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on VRTX shares. HC Wainwright reaffirmed a "buy" rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. Morgan Stanley reduced their price objective on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating for the company in a research report on Friday, June 20th. Erste Group Bank cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Scotiabank reduced their price objective on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a research report on Tuesday, May 6th. Finally, Wolfe Research cut shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, May 7th. Fourteen equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $512.30.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Vertex Pharmaceuticals stock. Brighton Jones LLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 15.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,427 shares of the pharmaceutical company's stock after acquiring an additional 579 shares during the quarter. Brighton Jones LLC's holdings in Vertex Pharmaceuticals were worth $1,783,000 at the end of the most recent quarter. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.